Clinical Trials Logo
  1. Home
  2. Neoplasm Malignant
  3. NCT06238687

A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors

Neoplasm Malignant Clinical Trial

Official title:
A Phase I/IIa Study to Evaluate the Safety, Tolerability , Pharmacokinetics and Preliminary Efficacy of STRO-002 in Chinese Adults With Advanced Epithelial Ovarian Cancer, Endometrial Cancer, and Other Advanced Malignant Solid Tumors.

Clinical Trial Summary

This is a multi-center, open-label, monotherapy dose escalation, PK bridging, and dose expansion Phase I/IIa study in Chinese adult subjects to evaluate the safety, tolerability, Pharmacokinetics (PK) profiles, immunogenicity, and preliminary efficacy of STRO-002 in patients with advanced malignant solid tumors.

Clinical Trial Description

This study consists of two parts, Phase I (dose escalation and PK bridging) and Phase IIa (dose expansion). Subjects in each cohort of Phase I will be administered 3 scheduled dose levels of STRO-002 as monotherapy by intravenous infusion until intolerable toxicity, radiographic disease progression, or subject withdrawal for other reasons. 5 dose arms are tentatively set based on the available safety, PK and efficacy data of STRO-002 for the Phase IIa (dose expansion). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06238687
Study type Interventional
Source Tasly Pharmaceutical Group Co., Ltd
Contact Kongli zhu
Phone +8615800363686
Email tsl-zhukongli@tasly.com
Status Recruiting
Phase Phase 1/Phase 2
Start date November 8, 2023
Completion date December 30, 2027
View Details
See also
  Status Clinical Trial Phase
Completed NCT01156870 - First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor Phase 1
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Completed NCT01930552 - A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies Phase 1
Completed NCT01657214 - Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients Phase 1
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Completed NCT02575781 - A Study of SAR428926 in Patients With Advanced Solid Tumors Phase 1
Completed NCT01943838 - A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma Phase 1
Completed NCT03324113 - Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors Phase 1
Completed NCT02435121 - A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification Phase 2
Completed NCT01985191 - A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients Phase 1
Completed NCT01455532 - A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors Phase 1
Active, not recruiting NCT03491631 - Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04067388 - iKnife REIMS Project
Completed NCT01836705 - Effect of SAR302503 on ECG Activity in Patients With Solid Tumors Phase 1
Completed NCT01140607 - Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment Phase 1
Recruiting NCT04495790 - AIMS Cancer Outcomes Study
Recruiting NCT05714553 - NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Phase 1/Phase 2
Recruiting NCT04733469 - EMPOWER 3: Improving Palliative Care Health Literacy and Utilization N/A
Active, not recruiting NCT03845166 - A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors Phase 1
Completed NCT01596270 - A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma Phase 1